European Society of Cardiology
Skip navigation links
Home
About the ESC
Membership
Communities
Congresses
Education
Guidelines & Surveys
Journals
Initiatives
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe
 

Biomarker test for Peripartum Cardiomyopathy could help reduce death after giving birth 

 

Topics: Heart Failure (HF)
Date: 17 May 2014
Athens, 17 May 2014: Cardiologists have discovered biomarkers that can be used to develop a screening test to detect Peripartum Cardiomyopathy (PPCM), a life-threatening disorder that is the primary cause of mortality in pregnant women in developing countries. The results, which can lead to the immediate treatment of PPCM in new mothers and a significant reduction in mortality, were presented at Heart Failure 2014, which opened the World Congress on Acute Heart Failure in Athens the 17 to the 20 May.
"For pregnant women there are two major causes of death: massive hemorrhage and PPCM, and it is a very sad situation because a time of great happiness turns to great sorrow and the new baby and the father are left alone," said study co-author Professor Alexandre Mebazaa, from the Hopital Lariboisiere, Paris. "Here we have found a way to detect rather quickly whether the woman has PPCM and to treat it quickly and efficiently."
PPCM is the leading cause of death in women who are pregnant or have just given birth in Haiti, South African and Egypt, according to the study's authors. Treatment was often delayed because it was difficult to know whether the women were experiencing normal symptoms of pregnancy or PPCM. The new discovery will allow doctors to administer a blood test to determine whether the woman has PPCM and begin effective treatment immediately.
"There's an urgent need for biomarkers of PPCM since the condition can be hard to differentiate from the normal symptoms of pregnancy that include dyspnoea, oedema and palpitations," said Professor Karen Sliwa, a co-author from the University of Cape Town, South Africa.
The authors hypothesized that since angiogenesis and relaxin-2 pathways are altered in PPCM the biomarkers ratio of these two pathways placental growth factors/sFlt-1 and relaxin-2 could be used to discriminate PPCM among peripartum women.

In the study, plasma was withdrawn from 77 PPCM patients, 75 healthy peripartum women, 25 breast feeding mothers, and 65 non-pregnant acute heart failure (HF) patients and tested for levels of cardiovascular (NT-proBNP), anti- (sFlt-1) and angiogenic [Placental (PlGF) or vascular endothelial (VEGF)] .

Results showed that compared to the other groups, PPCM patients had significantly higher levels of NT-proBNP, lower levels of plasma relaxin-2, and that the sFlt-1/PlGF ratio and sFlt-1/VEGF ratio were statistically lower.
“The next step will be to confirm our findings in a larger cohort and if they hold we could go on to develop a bed side test similar to NT-pro BNP in HF,” said Professor Sliwa.

Authors: ESC Press Office
Jacqueline Partarrieu
press@escardio.org
Tel: +33 6 22 83 45 76

Notes to editor

About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean.  Its mission is to reduce the burden of cardiovascular disease in Europe.

About the Heart Failure Association (HFA)
The Heart Failure Association (HFA) is a registered branch of the ESC. Its aim is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.

For practical information about heart failure aimed at patients, families and caregivers, visit the HFA’s Heart Failure Matters website

Did you want to tweet about our congress? - if you do, please use the official #heartfailure2014 hashtag! Thank you

Information for journalists attending Heart Failure 2014

  • If you have any questions or requests regarding interview opportunities, please contact:

ESC Press Office
Jacqueline Partarrieu
press@escardio.org
Tel: +33 6 22 83 45 76 (off site support number)

  • Heart Failure 2014 takes place in Athens, Greece, from 17-20 May 2014 at the MAICC Congress Center. 
  • Look here for the current final programme.
  • For full details of a session, have a look at the Scientific Programme & Planner  
  • On-site Press registration process:
    • Free registration applies to press representatives upon receipt of valid credentials and a fully completed embargo form. 
    • Credential: either your ID press card or letter of assignment with proof of 3 published articles
    • Press registration is not available to Industry or its Public Relations representatives, event management, marketing or communications representatives
    • The decision of the ESC Press Office is final regarding all press registration requests.
    • When your registration as press will be validated you will be given a press badge and the press kit.
    • The press working area is located in front of the registration desks. It features free wifi and a printer linked to a computer.